Fibrocell Science (FCSC) Sees Large Volume Increase
Shares of Fibrocell Science Inc (NASDAQ:FCSC) saw unusually-strong trading volume on Wednesday . Approximately 8,612,477 shares traded hands during trading, an increase of 2,921% from the previous session’s volume of 285,053 shares.The stock last traded at $2.35 and had previously closed at $1.97.
Several equities research analysts recently weighed in on FCSC shares. Zacks Investment Research downgraded shares of Fibrocell Science from a “buy” rating to a “hold” rating in a research report on Wednesday, February 13th. ValuEngine raised shares of Fibrocell Science from a “sell” rating to a “hold” rating in a research report on Wednesday, January 2nd. Two research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of $11.33.
The stock has a market cap of $17.95 million, a price-to-earnings ratio of -0.28 and a beta of 1.60.
Fibrocell Science Company Profile (NASDAQ:FCSC)
Fibrocell Science, Inc, an autologous cell and gene therapy company, focuses on discovering and developing therapies for diseases affecting the skin and connective tissues in the United States. The company's gene therapy product candidates include FCX-007 that is in Phase I/II clinical trials to treat recessive dystrophic epidermolysis bullosa; FCX-013, a gene therapy for localized scleroderma; and gene-therapy program that is in research phase to arthritis and related conditions.
See Also: Yield Curve
Receive News & Ratings for Fibrocell Science Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fibrocell Science and related companies with MarketBeat.com's FREE daily email newsletter.